Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 270

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 270
---
 is a forward-looking
statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors
discussed in the section entitled “Risk Factors” and elsewhere in this proxy statement/prospectus. DiamiR has based this estimate
on assumptions that may prove to be wrong, and it could utilize its available capital resources sooner than currently expected.

DiamiR’s future funding
requirements, both near- and long-term, will depend on many factors, including, but not limited to:

| ● | the initiation, progress, timing, costs, and results of clinical 
 validation for CogniMIR®                                         |

| ● | the terms and timing of any future collaboration, licensing, 
 or other arrangements that DiamiR may establish;             |

| ● | the outcome, timing, and cost of meeting regulatory requirements; |

| ● | the cost of obtaining, maintaining, defending, and enforcing 
 intellectual property rights, including patent rights;       |

| ● | the effect of competing technological and market developments; |

| ● | market acceptance of CogniMIR® if DiamiR meets         
 regulatory requirements for its commercialization; and |

| ● | the extent to which DiamiR acquires, licenses, or invests 
 in businesses, products or technologies.                  |

<div align='center'>150</div>

Until DiamiR can generate a
sufficient amount of revenue from CogniMIR and related services and products, if ever, DiamiR expects to finance future
cash needs through public or private equity offerings, debt financings or grants. Additional funds may not be available when needed on
terms that are acceptable to DiamiR, or at all. If adequate funds are not available, DiamiR may be required to delay, reduce the scope
of or eliminate its commercialization efforts. To the extent that DiamiR raises additional funds by issuing shares of common stock, its
shareholders may experience additional dilution, and debt financing, if available, may involve restrictive covenants. To the extent that
DiamiR raises additional funds through collaborations and licensing arrangements, it may be necessary to relinquish some rights to its
technologies or its product candidates or grant licenses on terms that may not be favorable to DiamiR. DiamiR may seek to access
the public or private capital markets whenever conditions are favorable, even if DiamiR does not have an immediate need for additional
capital at that time.